COVID-19-Associated Telogen Effluvium After Hospital Discharge: A Prospective Cohort Study

    March 2024 in “ PubMed ”
    Katerina Damevska, Tomica Sotirovski, Bojana Batkoska, Marija Djambazova, Vaska Radeski, Jorde Simonoska, Dimitri Bachevski, Kujtime Rushiti Mehmeti, Tomche Popovski, Ermira Labenishta, Aleksandar Ristovski, Anita Najdova
    Image
    Studysummary This study found a high prevalence of telogen effluvium among patients hospitalized for severe COVID-19, with most experiencing early onset and eventual complete hair regrowth. Our plain-language summary of this paper — not a Tressless recommendation.
    This prospective cohort study assessed the prevalence of telogen effluvium (TE) in 77 patients hospitalized for severe COVID-19. Results showed that 68.8% of patients experienced TE, with 52.8% reporting early onset and 50.9% reporting moderate hair loss. Complete hair regrowth occurred in 20.7% of patients within three months and in 60.3% within six months, while 7.5% had chronic TE. Female sex, anemia, hypoproteinemia, and severe pneumonia were significantly associated with TE. The study highlights a high prevalence of COVID-19-associated TE, which generally has a good prognosis but can lead to chronic TE in a minority of cases.
    Discuss this study in the Community →